Lifescience

  The global gammaretroviral vector market was valued at USD 5.95 billion in 2024 and is projected to reach USD 16.66 billion by 2031 , growing at a strong CAGR of 16.2% during the forecast period. "Comprehensive Insights: Download Our Latest Industry Report" Gammaretroviral vectors are critical tools in gene therapy and gene transfer research , valued for their efficient integration capabilities and simple genomic structure. These viral vectors, including Moloney murine leukemia virus (MoMLV) and feline leukemia virus , integrate stable genetic material into the host genome, making them essential in therapeutic development. Their adoption is accelerating as healthcare systems globally seek advanced therapies to treat cancer, genetic disorders, and infectious diseases. Market Highlights The gammaretroviral vector market is experiencing rapid expansion driven by: ·          Rising prevalence of cancer , including lung, breast, a...

  The global vaccines digital biomanufacturing market size was valued at USD 460 million in 2024 and is projected to grow from USD 512 million in 2025 to USD 957 million by 2032 , at an impressive CAGR of 11.2% during the forecast period. Vaccines digital biomanufacturing integrates artificial intelligence (AI), Internet of Things (IoT) sensors, big data analytics, and digital twins into biological production systems. By enhancing real-time monitoring, predictive maintenance, and automated quality control, this digital approach enables faster, more efficient, and scalable vaccine production. The technology proved particularly critical during pandemic responses, where rapid vaccine development and deployment were paramount. "Comprehensive Insights: Download Our Latest Industry Report" Market Highlights The market’s expansion is driven by: ·          Rising global demand for rapid vaccine production and scalable infrastructure. ...

  The global biologics and biosimilars market size was valued at USD 373.81 billion in 2024 and is projected to grow from USD 408.75 billion in 2025 to USD 690.86 billion by 2032 , at a steady CAGR of 9.4% during the forecast period. "Comprehensive Insights: Download Our Latest Industry Report" Biologics are complex therapeutics derived from living organisms, including monoclonal antibodies, vaccines, recombinant proteins, and gene therapies , widely used in the treatment of cancer, autoimmune conditions, diabetes, and infectious diseases. Biosimilars , as highly similar alternatives to approved biologics, offer cost-effective solutions while maintaining comparable safety and efficacy, making them crucial in expanding access to advanced therapies. Market Highlights The market growth is fueled by: ·          Rising prevalence of chronic diseases such as cancer and autoimmune disorders. ·       ...